Staggs PLLC

ABOUT
EVENTS
RESOURCES
CONTACT

More ...

More ...

More ...

CLIENT FOCUS

Staggs PLLC can help you develop a portfolio of intellectual property assets that strengthen your company. Our technical background allows us to work efficiently with your team to draft comprehensive patent applications. We may also be able to strengthen your existing applications through the filing of continuations.

Staggs PLLC will take your ideas step by step through the US patent process, giving your invention the protection it deserves.

Technology background
Fee structure options

TECH NOTES

APIs PROTECTED BY COPYRIGHT

Use of popular Application Programming Interfaces (APIs) can expose your business to liability under copyright law.
read more

INTERNET TRUST

Trust over the Internet is vital but current solutions are imperfect. This scenario can encourage innovative approaches to security.
read more

RESTFUL COMMUNICATION

The most popular architectural style for exchanging information between computers on the Internet is Representational State Transfer (REST). Learn about the intersection of REST technology and patent applications.
read more

PROTECTING APIs

Secure access from mobile platforms to state-of-the-art applications creates an opportunity to develop new products. OAuth and UMA could be useful in your next release.
read more

NEWS & UPDATES

GENERAL NEWS
July 1, 2018

Apple v. Samsung has changed US design patent law.

December 21, 2017

Surprisingly strong number of filings in the Eastern District of Texas.

May 27, 2017

U. S. Supreme Court severely limits where patent holders can sue infringers.

Mar 1, 2017

Apple v. Samsung $399M design patent damage award now in doubt.

February 15, 2017

CRISPR interference between MIT and UC Berkeley terminated.

December 15, 2016

Delaware jury awards $2.5 billion for patent infringement.

October 3, 2016

USPTO publishes proposed fee increases in the Federal Register.

June 13, 2016

Award of enhanced damages for patent infringement just got easier.

May 2, 2016

Spike in examiner rejections of personalized medicine patent applications.